Effect of Helicobacter pylori eradication on gastric histology and symptom resolution in functional dyspepsia: a preliminary follow-up study
DOI:
https://doi.org/10.18203/2349-2902.isj20253024Keywords:
Symptom resolution, Modified Sydney system, Helicobacter pylori eradication, Gastric histopathology, Functional dyspepsiaAbstract
Background: Functional dyspepsia (FD) is a prevalent gastrointestinal condition with a multifactorial origin, in which Helicobacter pylori infection may play a contributory role. Although eradication therapy has been shown to offer symptomatic relief in a subset of patients, predictors of response remain inadequately defined. To evaluate the effect of H. pylori eradication on gastric histological parameters and symptom resolution in patients with functional dyspepsia and to identify histopathological predictors of treatment response.
Methods: This prospective observational study included 121 adult patients with functional dyspepsia and confirmed H. pylori infection. All patients underwent upper gastrointestinal endoscopy and gastric biopsies were obtained before initiating eradication therapy. Biopsy specimens were stained with H&E and Giemsa and histological assessment was performed by a blinded pathologist using the Modified Sydney System. Parameters assessed included chronic inflammation, neutrophilic activity, glandular atrophy, intestinal metaplasia and H. pylori density. A composite Sydney score was calculated. Follow-up was conducted at 3 months to assess symptom resolution. Patients were categorized into "Resolved" and "Non-improved" groups based on symptomatic outcomes.
Results: Out of 100 patients enrolled, follow-up data were available for 79. Symptom resolution was observed in 52 patients (51.5%), while 27 (26.7%) reported no improvement. Patients with symptom resolution had significantly higher pre-treatment scores for chronic inflammation (p=0.012), neutrophilic activity (p=0.021), H. pylori density (p=0.008) and composite Sydney score (p=0.002). Glandular atrophy (p=0.486) and intestinal metaplasia (p=0.671) showed no significant association with symptomatic improvement.
Conclusions: Symptomatic benefit following H. pylori eradication in functional dyspepsia appears to be associated with higher baseline levels of chronic and active gastric inflammation, as well as H. pylori density. Histopathological assessment using the Modified Sydney System may help predict treatment response and guide clinical decision-making.
Metrics
References
Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22(6):729-41. DOI: https://doi.org/10.1080/14656566.2020.1845649
Koloski NA, Jones M, Walker MM, Holtmann G, Talley NJ. Functional dyspepsia is associated with lower exercise levels: a population-based study. United Eur Gastroenterol J. 2020;8(5):577-83. DOI: https://doi.org/10.1177/2050640620916680
Sadowski DC, van Zanten SV. Dyspepsia. CMAJ. 2015;187(4):276. DOI: https://doi.org/10.1503/cmaj.141606
Huang TT, Cao YX, Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024;15:1418129. DOI: https://doi.org/10.3389/fmicb.2024.1418129
Fu Q, Yu H, Liu M, Chen L, Chen W, Wang Z, et al. Effect of Helicobacter pylori eradication on gastric cancer risk in patients with intestinal metaplasia or dysplasia: a meta-analysis of randomized controlled trials. Front Microbiol. 2025;16:1530549. DOI: https://doi.org/10.3389/fmicb.2025.1530549
Wang J, Gu S, Qin B. Efficacy of Helicobacter pylori eradication therapy for treatment of functional dyspepsia: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(20):26045. DOI: https://doi.org/10.1097/MD.0000000000026045
Miftahussurur M, Alfaray RI, Rezkitha YAA, Fauzia KA, Maulahela H, Muzellina VN, et al. Macronutrient and micronutrient intake in dietary habits contributed to dyspeptic symptoms in Indonesia. Gac Med Caracas. 2022;130(2):266-75. DOI: https://doi.org/10.47307/GMC.2022.130.2.6
Zhou BG, Jiang X, Ding YB, She Q, Li YY. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2024;29(1):13040. DOI: https://doi.org/10.1111/hel.13040
Azadbakht S, Azadbakht S, Esmaili A, Rahmani P. Comparison of clinical symptoms after Helicobacter pylori eradication in functional dyspepsia patients based on endoscopic view of antral gastropathy. New Microbes New Infect. 2020;38:100806. DOI: https://doi.org/10.1016/j.nmni.2020.100806
Zhao Y, Li Y, Hu J, Wang X, Ren M, Lu G, et al. The effect of Helicobacter pylori eradication in patients with gastroesophageal reflux disease: a meta-analysis of randomized controlled studies. Dig Dis. 2020;38(4):261-8. DOI: https://doi.org/10.1159/000504086
Hsu PI, Tsay FW, Kao JY, Peng NJ, Tsai KW, Tsai TJ, et al. Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2020;35(10):1731-7. DOI: https://doi.org/10.1111/jgh.15034
Ford AC, Moayyedi P, Black CJ, Yuan Y, Veettil SK, Mahadeva S, et al. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. Aliment Pharmacol Ther. 2021;53(1):8-21. DOI: https://doi.org/10.1111/apt.16072
Zhao B, Zhao J, Cheng WF, Shi WJ, Liu W, Pan XL, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol. 2014;48(3):241-7. DOI: https://doi.org/10.1097/MCG.0b013e31829f2e25
Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. A triple-drug blister-packaged drug with vonoprazan improves first-line eradication of Helicobacter pylori in elderly patients: a retrospective propensity score-matched cohort study. Digestion. 2020;101(5):608-14. DOI: https://doi.org/10.1159/000501608
Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10(3):168-74. DOI: https://doi.org/10.1038/nrgastro.2013.9
Downloads
Published
How to Cite
Issue
Section
